FINNENCE ▪ THE WIRE FILE
THE WIRE · № 60913
Company■ Unclear/unknown
New Phase 3 trial: A Study to Evaluate the Immune Response and Safety of a Vaccine Against Influenza in Adults 18-64 Years of Age — GlaxoSmithKline
KINDCompany
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 12:00 UTC
LAST UPDATE2026-10-01 12:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A new mRNA flu vaccine Phase 3 expands GSK's mRNA platform but is years from commercialization.
GSK advances mRNA flu vaccine program
CATALYST TO WATCH
Interim immunogenicity and safety data
MAIN RISK
mRNA flu efficacy may lag conventional
FULL DISPATCH
Sponsor: GlaxoSmithKline; Status: Not Yet Recruiting; Conditions: Influenza, Human; Interventions: mRNA Seasonal Flu vaccine, Comparator 1, Comparator 2; Enrollment: 3000 (estimated); First posted: 2026-10-01; NCT: NCT07851246
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC
Phase 3 results posted: A Study of Orforglipron (LY3502970) in Participants With Type 2 Diabetes and Inadequate Glycemic Control With Insulin Glargine, With or Without Metformin and/or SGLT-2 Inhibitor — Eli Lilly and Company2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: Atacicept in Subjects With IgA Nephropathy — Vera Therapeutics, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: A Study Evaluating the Efficacy and Safety of SM04554 Topical Solution in Male Subjects With Androgenetic Alopecia — Biosplice Therapeutics, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
Phase 3 results posted: Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III) — BioXcel Therapeutics Inc2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Abcuro, Inc.2026-10-01 12:00 UTC
Phase 3 results posted: A Study to Evaluate the Efficacy and Safety of ABC008 for Inclusion Body Myositis — Abcuro, Inc.2026-10-01 12:00 UTC
→CORRELATIONshares Healthcare
Quadria-backed Maxivision confidentially files for India IPO2026-10-01 23:00 UTC
Quadria-backed Maxivision confidentially files for India IPO2026-10-01 23:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.